Faculty Profiles - TOYOOKA Shinichi

MISC - TOYOOKA Shinichi

Division display 681 - 700 of about 703 ／ All the affair displays >>

悪性胸膜中皮腫における異常メチル化とSV40との関連(第105回日本外科学会定期学術集会)

鈴木実, 豊岡伸一, 重松久之, 高橋孝夫, 宮島邦治, 木村秀樹, 藤澤武彦

日本外科学会雑誌 106 270 - 270 2005.4

The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers

Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar AF, Shimizu N

Clin Cancer Res 2005

Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers.

Yano M, Toyooka S, Tsukuda K, Dote H, Ouchida M, Hanabata T, Aoe M, Date H, Gazdar AF, Shimizu N

Int J Cancer 2005

The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer.

Sekine I, Sato M, Sunaga N, Toyooka S, Peyton M, Parsons R, Wang W, Gazdar AF, Minna JD

Oncogene. 2005

P11-25 非小細胞肺癌におけるGefitinibの効果とEGFR遺伝子変異の検討(ポスター総括11 : 基礎分子標的1(トランスレーショナルリサーチ))

豊岡伸一, 徳毛誠樹, 木浦勝行, 青江基, 田端雅弘, 重松久之, 市村浩一, 末久弘, 永広格, 岡部和倫, 佐野由文, 伊達洋至, 上岡博, 谷本光音, 清水信義

肺癌 44 ( 5 ) 642 - 642 2004.10

OP-1-125 ヒト胃癌および大腸癌におけるIGFBP-3発現低下と異常メチル化の解析(研究2)

富井邦年, 佃和憲, 豊岡伸一, 土手秀昭, 矢野匡亮, 浅野博昭, 村上正和, 太田徹哉, 内藤稔, 清水信義

日本消化器外科学会雑誌 37 ( 7 ) 1074 - 1074 2004.7

PS-155-4 Epigenetic regulation of the cyclooxgenase-2(COX-2) gene in lungcancer cell lines

Adi Gazdar

Journal of Japan Surgical Society 105 578 - 578 2004.3

Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer.

Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF, Shimizu N

Clin Cancer Res 2004

Aberrant methylation o p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.

Kobatake T, Yano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T, Toyota M, Ouchida M, Aoe M, Date H, Pass HI, Diohara H, Shimizu N

Oncol Rep 2004

Tumor-specific exon creation of the HELLS/SMARCA6 gene in non-small cell lung cancer

Yano Masaaki, Ouchida Mamoru, Shigematsu Hisayuki, Tanaka Noriyoshi, Ichimura Koichi, Kobayashi Kazuyasu, Inaki Yasuhiko, Toyooka Shinichi, Tsukuda Kazunori, Shimizu Nobuyoshi, Shimizu Kenji

International Journal of Cancer 112 ( 1 ) 8 - 13 2004

Dose effect of smiking on aberrant methlation in non-small cell lung cancers.

Toyooka S, Suzuki M, Tsuda T, Toyooka OK, Maruyama R, Tsukuda K, Fukuyama Y, Iizasa T, Fujisawa T, Shimizu N, Minna JD, Gazadar AF

Int J Cancer 2004

Models for studying DNA methylation in human cancer: A review of current status

Shinichi Toyooka, Nobuyoshi Shimizu

Drug Discovery Today: Disease Models 1 ( 1 ) 37 - 42 2004

Language：English Publishing type：Book review, literature introduction, etc. Publisher：Elsevier Ltd

In cancer epigenetics, aberrant methylation in the promoter is one of the key mechanisms for gene inactivation resulting in carcinogenesis in humans. Unique models have been utilized for studying methylation, for example, to determine the methylation profile, to study the mechanisms of methylation, and to investigate therapeutic interventions against cancer In humans. It is considered that further development of would be highly useful for further understanding and controlling cancer in humans. © 2004 Elsevier Ltd. All rights reserved.

DOI： 10.1016/j.ddmod.2004.01.002

Scopus

researchmap

RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells.

Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF, Minna JD

Cancer Res. 64 ( 9 ) 3137 - 43 2004

肺癌におけるDAB2IP遺伝子のDNAメチル化と発現の解析

矢野匡亮, 豊岡伸一, 永廣格, 佐野由文, 青江基, 伊達洋至, 青水信義

肺癌 43 ( 5 ) 494 - 494 2003.10

胃癌におけるhDAB2IP遺伝子のhypermethylation解析

土手秀昭, 豊岡伸一, 佃和憲, 矢野匡亮, 戸田大作, 渡辺啓太郎, 太田徹哉, 村上正和, 内藤稔, 清水信義

日本消化器外科学会雑誌 36 ( 7 ) 1083 - 1083 2003.7

乳癌におけるhDAB2IP遺伝子のhyper-methylation解析

土手秀昭, 豊岡伸一, 佃和憲, 矢野匡亮, 太田徹哉, 内藤稔, 村上正和, 土井原博義, 清水信義

日本外科学会雑誌 104 447 - 447 2003.4

食道扁平上皮癌に対するin vitro,in vivoにおける,ZD1839(Iressa)の抗腫瘍効果に関する検討

原文堅, 平成人, 枝園忠彦, 高橋寛敏, 吉冨誠二, 石部洋一, 豊岡伸一, 太田徹哉, 青江基, 土井原博義, 清水信義

日本外科学会雑誌 104 662 - 662 2003.4

The TP53 Gene, Tobacco Exposure, and Lung Cancer.

Toyooka S, Tsuda T, Gazdar A.F

Human Mutation 2003

OP-2-043 大腸腫瘍におけるH-cadherin(CDH13)遺伝子のメチル化と発現異常

豊岡伸一, 佃和憲, 原田賢一, 村上正和, 太田徹哉, 内藤稔, F. Gazdar Adi, 清水信義

日本消化器外科学会雑誌 35 ( 7 ) 976 - 976 2002.7

Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression

David G. Burbee, Eva Forgacs, Sabine Zöchbauer-Müller, Latha Shivakumar, Kwun Fong, Boning Gao, Dwight Randle, Masashi Kondo, Arvind Virmani, Scott Bader, Yoshitaka Sekido, Farida Latif, Sara Milchgrub, Shinichi Toyooka, Adi F. Gazdar, Michael I. Lerman, Eugene Zabarovsky, Michael White, John D. Minna

Journal of the National Cancer Institute 93 691 - 699 2001.5

Background: The recently identified RASSF1 locus is located within a 120-kilobase region of chromosome 3p21.3 that frequently undergoes allele loss in lung and breast cancers. We explored the hypothesis that RASSF1 encodes a tumor suppressor gene for lung and breast cancers. Methods: We assessed expression of two RASSF1 gene products, RASSF1A and RASSF1C, and the methylation status of their respective promoters in 27 non-small-cell lung cancer (NSCLC) cell lines, in 107 resected NSCLCs, in 47 small-cell lung cancer (SCLC) cell lines, in 22 breast cancer cell lines, in 39 resected breast cancers, in 104 nonmalignant lung samples, and in three breast and lung epithelial cultures. We also transfected a lung cancer cell line that lacks RASSF1A expression with vectors containing RASSF1A complementary DNA to determine whether exogenous expression of RASSF1A would affect in vitro growth and in vivo tumorigenicity of this cell line. All statistical tests were two-sided. Results: RASSF1A messenger RNA was expressed in nonmalignant epithelial cultures but not in 100% of the SCLC, in 65% of the NSCLC, or in 60% of the breast cancer lines. By contrast, RASSF1C was expressed in all nonmalignant cell cultures and in nearly all cancer cell lines. RASSF1A promoter hypermethylation was detected in 100% of SCLC, in 63% of NSCLC, in 64% of breast cancer lines, in 30% of primary NSCLCs, and in 49% of primary breast tumors but in none of the nonmalignant lung tissues. RASSF1A promoter hypermethylation in resected NSCLCs was associated with impaired patient survival (P = .046). Exogenous expression of RASSF1A in a cell line lacking expression decreased in vitro colony formation and in vivo tumorigenicity. Conclusion: RASSF1A is a potential tumor suppressor gene that undergoes epigenetic inactivation in lung and breast cancers through hypermethylation of its promoter region.

DOI： 10.1093/jnci/93.9.691

　 PREV - NEXT 　

< TOYOOKA Shinichi >

MISC - TOYOOKA Shinichi